Guselkumab, an Inhibitor of the IL-23p19 Subunit, Provides Sustained Improvement in Signs and Symptoms of Active Psoriatic Arthritis: 1 Year Results of a Phase III Randomised Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
RMD open（2021）
关键词
arthritis,psoriatic,biological therapy,tumor necrosis factor inhibitors,cytokines
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要